Biotech · Public company · Mountain View, CA, US
Alto Neuroscience, Inc.
Ticker ANRO · SEC CIK 0001999480
Track this companyFree. Adds Alto Neuroscience, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials104 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline11
- ALTO-100Phase 2 · Bipolar Disorder I or II With a Major Depressive EpisodeClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-100Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-100 PO TabletPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-101Phase 2 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-101 Transdermal Delivery SystemPhase 2 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-203 25 μgPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-203 75 μgPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-207Phase 2 · Treatment-resistant Depression (TRD)ClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-300Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-300 oral (PO) tabletPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ALTO-300 PO TabletPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- ALTO-207 in Adults With Treatment-resistant Depression (TRD)PHASE2 · RECRUITING · started May 20, 2026ClinicalTrials.gov NCT07553637 · fetched Nov 12, 2026
- ALTO-100 in Bipolar Disorder With Depression (BD-D)PHASE2 · RECRUITING · started Oct 2, 2024ClinicalTrials.gov NCT06656416 · fetched Nov 12, 2026
- Study of ALTO-101 in Patients With SchizophreniaPHASE2 · RECRUITING · started Jun 11, 2024ClinicalTrials.gov NCT06502964 · fetched Nov 12, 2026
- PD, PK, and Safety of ALTO-203 in Patients With MDDPHASE2 · COMPLETED · started Mar 25, 2024ClinicalTrials.gov NCT06391593 · fetched Nov 12, 2026
- Study of ALTO-300 in MDDPHASE2 · RECRUITING · started Jun 8, 2023ClinicalTrials.gov NCT05922878 · fetched Nov 12, 2026
- Phase 2b Study of ALTO-100 in MDDPHASE2 · COMPLETED · started Jan 10, 2023ClinicalTrials.gov NCT05712187 · fetched Nov 12, 2026
- Pilot Decentralized TrialPHASE2 · COMPLETED · started Jun 1, 2022ClinicalTrials.gov NCT05419869 · fetched Nov 12, 2026
- ALTO-300 in Depression (ALTO-300-004)PHASE2 · COMPLETED · started Feb 3, 2022ClinicalTrials.gov NCT05157945 · fetched Nov 12, 2026
- ALTO-100 in MDD and/or PTSDPHASE2 · COMPLETED · started Dec 20, 2021ClinicalTrials.gov NCT05117632 · fetched Nov 12, 2026
- ALTO-300 in DepressionPHASE2 · COMPLETED · started Dec 13, 2021ClinicalTrials.gov NCT05118750 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 27, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Apr 1, 2026 · fetched Nov 12, 2026